Extended Data Fig. 3: Development and characterization of lipidated daLUXendin660+.
From: Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
a) daLUXendin660 can be further modified to generate daLUXendin660+ by installing a C20 di-acid lipid chain at lysine position 20. b) cAMP responses to daLUXendin660 (daLUX660) and daLUXendin660+ (daLUX660+) in AD293 cells expressing either human (h)GLP1R, mouse (m)GLP1R, human (h)GIPR or mouse (m)GIPR (n = 4 independent repeats). c, d) Binding affinity of daLUXendin660+ against hGLP1R and hGIPR (c), with Kd values (d) in a separate bar graph (one-site fit specific binding) (n = 3 independent repeats). e-h) daLUX660+ labels islets similarly to daLUX660, with strength of labelling β cells > α cells = δ cells, as shown by representative images (e, g) and summary bar graphs (f, h) (INS, insulin = at least 26 islets from 5 mice; GCG, glucagon = at least 16 islets from 5 mice; SST, somatostatin = at least 16 islets from 5 mice) (Kruskal-Wallis test with Dunn’s multiple comparisons test). Scale bar = 53 µm. Scatter plots and line graphs show mean ± SEM. Violin plots shows min-max and median. Exact p values are displayed on each graph.
